pdufa.bio
CalendarDecisionsReadoutsPatents
Drug IndexStocksScreenerConferencesAdvisory Committees
StudiesRun-up by YearLearnGlossaryMethodologyAPIAccount
Pro
Home › PDUFA Calendar › PHVS

Pharvaris N.V. (PHVS) FDA catalysts & readout calendar

Updated ·next FDA decision on the calendar
Pharvaris N.V. · 1 upcoming · 0 past FDA decisions

Upcoming FDA catalysts

PHVS · Apr 23, 2027Deucrictibant IR - (RAPIDe-3): Hereditary angioedema, on-demand

Clinical readouts (1)

2026-09deucrictibant readout
Full PDUFA calendar →All FDA decisions →Phase readouts →
See the full 2026 PDUFA calendar →

This page aggregates PHVS's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.

Common questions

When is the next FDA decision or readout for Pharvaris N.V. (PHVS)?

Q3 2026. The next catalyst for Pharvaris N.V. is deucrictibant readout. That date is known to the quarter only. One further catalyst is scheduled after it. Dates are taken from FDA notices, company filings or ClinicalTrials.gov, and we do not publish a specific day when the source only gives a month or a quarter.

How do stocks like PHVS move into an FDA decision?

We have no measured history for PHVS itself. Across the whole study of 1,839 FDA decisions, the median stock rose 17.7% at its best point in the 120 trading days before the decision, but was only 2.0% higher the day before it. Most of the move happened before the answer arrived and was largely given back.

Where does this PHVS data come from?

FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Every date and outcome links the document it came from. Where an outcome was inferred from the price reaction rather than read from a filing, the page says so on its face.